Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Structure Therapeutics (GPCR) Shares Issued (2022 - 2026)

Quarterly Shares Issued fell 9.95% to $869000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $60.6 million through Mar 2026, up 2836.92% year-over-year, with the annual reading at $4.5 million for FY2025, 144.07% up from the prior year.

Structure Therapeutics' Shares Issued history spans 5 years, with the latest figure at $869000.0 for Q1 2026.

  • Shares Issued came in at $869000.0 for Q1 2026, down from $3.1 million in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $513.8 million in Q2 2024 to a low of -$512.9 million in Q3 2024.
  • The 5-year median for Shares Issued is $812000.0 (2024), against an average of $26.0 million.
  • Year-over-year, Shares Issued skyrocketed 1531.03% in 2023 and then plummeted 108544.61% in 2024.
  • Structure Therapeutics' Shares Issued stood at $29000.0 in 2022, then skyrocketed by 1032027.59% to $299.3 million in 2023, then plummeted by 99.93% to $224000.0 in 2024, then skyrocketed by 1301.79% to $3.1 million in 2025, then plummeted by 72.32% to $869000.0 in 2026.
  • Per Business Quant, the three most recent readings for GPCR's Shares Issued are $869000.0 (Q1 2026), $3.1 million (Q4 2025), and $57.1 million (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Shares Issued (Qtr)
1 Quantum Biopharma 1,384,976.65 Bn 1,384,976.64 Bn - 5.40 Mn
2 Alterity Therapeutics 777,208.84 Bn 777,208.81 Bn - -
3 Legend Biotech 2,801.00 Bn 2,800.10 Bn 242.10 Mn -
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn - -
5 Akari Therapeutics 605.66 Bn 605.66 Bn - -
6 Vertex Pharmaceuticals 110.17 Bn 102.92 Bn 2.59 Bn 27.00 Mn
7 Regeneron Pharmaceuticals 66.86 Bn 58.11 Bn 3.31 Bn 163.10 Mn
8 Evaxion A 65.12 Bn 65.10 Bn - -
9 Alnylam Pharmaceuticals 39.94 Bn 36.94 Bn 959.66 Mn 13.16 Mn
10 Structure Therapeutics 8.43 Bn 8.43 Bn - 869,000.00

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 869,000.00
Mar 31, 2026 869,000.00
Dec 31, 2025 3.14 Mn
Dec 31, 2025 3.14 Mn
Sep 30, 2025 57.10 Mn
Sep 30, 2025 57.10 Mn
Jun 30, 2025 -491,000.00
Jun 30, 2025 -491,000.00
Mar 31, 2025 965,000.00
Mar 31, 2025 965,000.00
Dec 31, 2024 224,000.00
Dec 31, 2024 224,000.00
Sep 30, 2024 -512.94 Mn
Sep 30, 2024 -512.94 Mn
Jun 30, 2024 513.82 Mn
Jun 30, 2024 513.82 Mn
Mar 31, 2024 755,000.00
Mar 31, 2024 755,000.00
Dec 31, 2023 299.32 Mn
Dec 31, 2023 299.32 Mn
Sep 30, 2023 473,000.00
Sep 30, 2023 473,000.00
Jun 30, 2023 -172.09 Mn
Jun 30, 2023 -172.09 Mn
Mar 31, 2023 172.30 Mn
Mar 31, 2023 172.30 Mn
Sep 30, 2022 29,000.00
Sep 30, 2022 29,000.00